(Reuters) - Pfizer Inc is in talks to buy rival drug maker Wyeth in a deal that could be valued at more than $60 billion, the Wall Street Journal said, citing people familiar with the matter.
The two sides have been in discussions for months and a deal is not imminent, the people told the paper.
The talks are fragile given recent market volatility and weak global economic conditions, and could collapse, the people told the paper.
(Reporting by Ajay Kamalakaran in Bangalore; Editing by Kim Coghill)
